Compare NBIX & LSCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | LSCC |
|---|---|---|
| Founded | 1992 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.6B |
| IPO Year | 1996 | 1994 |
| Metric | NBIX | LSCC |
|---|---|---|
| Price | $130.52 | $114.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 12 |
| Target Price | ★ $180.91 | $103.75 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | 0.02 |
| Revenue | $161,626,000.00 | ★ $385,961,000.00 |
| Revenue This Year | $24.73 | $36.12 |
| Revenue Next Year | $13.14 | $19.98 |
| P/E Ratio | ★ $27.48 | $5,686.50 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $105.50 | $43.90 |
| 52 Week High | $160.18 | $126.35 |
| Indicator | NBIX | LSCC |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 57.86 |
| Support Level | $124.62 | $82.20 |
| Resistance Level | $135.88 | N/A |
| Average True Range (ATR) | 3.58 | 5.00 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 59.98 | 44.55 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.